James Geraghty joined Third Rock in 2013. Having helped Genzyme launch rare disease therapies around the world, James assists the firm in creating companies focused on rare genetic diseases and supports existing portfolio companies in related spaces.
Prior to joining Third Rock, James served as Senior Vice President, North America Strategy and Business Development at Sanofi, where he spearheaded Sanofi’s strategy for international diabetes care.
Before Sanofi, James spent 20 years at Genzyme Corporation, most recently as Senior Vice President and an Officer. While at Genzyme, his roles included President of Genzyme Europe and General Manager of Genzyme's cardiovascular business. He also led strategic transactions that brought important new products into Genzyme. He served as a director of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation), where he was previously Chairman, President and CEO.
James also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases program, under which Genzyme helped develop innovative therapeutic programs on a non-commercial basis. He served as co-chair of the executive committee for BIO 2007, and continues to serve on the board of Bio Ventures for Global Health (BVGH).
A graduate of the Yale Law School, he has published articles in the Yale Law Journal, Health Affairs and other publications. He holds an MS from the University of Pennsylvania and a BA from Georgetown University.
Page last updated: October 20, 2014